Monitoring MRI changes before and during Radiotherapy Treatment of Brain Tumors

Completed

Conditions: brain metastasis
Glioblastoma
10029211

Registration Number: NL-OMON45550

Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 80

Inclusion Criteria

- Primary brain tumor (WHO IV, GBM); treated with fractionated radiotherapy with or without preceding surgery.
- Brain metastasis from a solid extracranial tumor, eligible for treatment with fractionated radiotherapy with or without preceding surgery
- Age 18 or older

Exclusion Criteria

- Patients receiving Whole brain radiation therapy (WBRT)
- Patiens with a poor kidney function (GFR <30 mL/min; Chronic kidney disease 4 and 5; patients on dialysis and patients with acute kidney insufficiency)
- Contrast enhancing lesions smaller than 5mm in it's largest dimension

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Difference in contrast enhancing tumor volume on Dynamic contrast-enhanced<br /><br>(DCE) sequences<br /><br>- Difference in location of the tumor. Measured by the shift of the centre of<br /><br>mass and the maximum distance between the tumor borders.<br /><br>- Difference in permeability of the blood vessels in the tumor<br /><br>- Difference in the perfusion rate in the tumor<br /><br>- Difference in diffusion (cellularity) of the tumor<br /><br>- Number of adjusted radiotherapy treatment plans in relation to peritumoral<br /><br>edema, the primary tumor and the tumor location</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Occurrence of side-effects due to radiotherapy, specifically the (time to)<br /><br>occurrence of radiation necrosis<br /><br>- Time to tumor progression<br /><br>- Overall survival </p><br>